Company Profile
Kidswell Bio develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology.
Its portfolio also includes GBS-007 for ophthalmic disease, and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy.
Its portfolio also includes GCT-102 for congenital entero-neuropathy, SQ-104 for osteonecrosis of the femoral head, modified thymidine kinase for glioblastoma, and Gene X for spinal cord injury. and changed its name to Kidswell Bio Corporation in July 2021. The company was formerly known as Gene Techno Science Co.,Ltd. Incorporated in 2001, the company is headquartered in Chuo, Japan.